17% of patients, with a positive predictive value

of 5.2%. The positive predictive value and the cancer detection rate were significantly higher with OC-Sensor than with HM-Jack (Table 3). Positive predictive values and cancer detection rates were also higher for male sex and older age groups as compared with the total population group. When advanced adenoma was used as the index lesion, a higher positive predictive value was seen check details with OC-Sensor as compared with HM-Jack, but advanced adenoma detection rates were similar between the 2 tests. As shown in Table 4, the interval cancer rate for OC-Sensor was lower than that for HM-Jack (30.7 vs 40.6 per 100,000 person-years), resulting in a significant difference in test sensitivities (80% vs 68%; P = .005). The test sensitivity for each FIT was, however, similar among different subgroups stratified according to sex and age. To consider adherence to the screening process, the 2-year sensitivity of the screening program was evaluated by including into the calculation of interval cancers those individuals who had positive FIT findings, followed by a negative assessment or no additional assessment.17 Using this approach, a significant

difference was again observed between the 2 FITs (OC-Sensor: 77%; 95% CI, 73%–81% vs HM-Jack: 67%; 95% CI, 60%–75%; P = .027). Taking into account the differences in baseline characteristics of the 2 screened populations, multivariate analyses with the adjustments of demographics, geography, and temperature, and hospital levels (an

indicator for the quality of confirmatory diagnosis as shown in Supplementary Table 5) Vorinostat purchase were performed. As shown in Table 5, findings were remarkably similar to those obtained from the univariate analyses: a higher positive predictive value for cancer detection and a lower interval cancer rate were noted for OC-Sensor as compared with HM-Jack, with the exception that no significant difference in the cancer detection rate was observed. Thymidine kinase With respect to detection of advanced adenoma, the positive predictive value remained higher for OC-Sensor as compared with HM-Jack, but the advanced adenoma detection rate was similar for the 2 tests. Regarding relative mortality rates between the 2 screened populations, the crude and adjusted (for age and sex) hazard ratios were estimated to be 1.21 (95% CI, 0.91–1.61) and 1.22 (95% CI, 0.92–1.63), respectively, when OC-Sensor was compared with HM-Jack; the difference between the 2 groups was not significant. Regarding the absolute mortality reduction with the adjustment of self-selection bias, the results were 11% (95% CI, 6%–16%) and 13% (95% CI, 7%–18%), respectively, for the OC-Sensor and HM-Jack, as compared with nonparticipants, given the screening rate of 21.4% during the study period; the difference between the 2 FITs remained nonsignificant (P = .20). Findings are presented in Table 6. Regarding the cancer stage for the overall population, the proportions of stage 0–I CRC were 21.1%, 47.3%, and 35.